Skip to content
Search

Latest Stories

RPS demands additional funding to support pharmacists fighting COVID-19  

The Royal Pharmaceutical Society (RPS) today called upon the government to provide “additional funding and resourcing” to support pharmacists battling COVID-19.

The demand is part of the “six essentials” the society has listed for the NHS and the government to act on “to ensure pharmacists can keep themselves safe, cope with demand and provide the best possible patient care.”


RPS said an NHS-funded delivery service is essential to cater to those unable to collect their medicines, particularly as the country toughens its approach in the fight against the virus.

Various trade bodies including the PSNC, National Pharmacy Association and National Association of Primary Care have been raising the demand of urgent funding support for pharmacies.

RPS has also demanded a change in law to minimise potential medicine shortages, by allowing community pharmacists “to use their professional judgement to help manage the supply of medicines without the bureaucracy that currently exists.”

The society said it will back pharmacists when they have to choose people over rules in the prevailing situation.

“There will be circumstances in the coming weeks where you’ll need to do things differently and prioritise putting people first and professional ethics over legislation, regulation and processes,” the RPS said in a communication.

“We can’t guarantee that questions won’t be asked about “why” you made particular decisions, however you can be reassured that we as an organisation will be supportive of using your professional judgement to help people.”

Other demands include adequate supplies of quality personal protection equipment and prioritised testing for pharmacy teams; inclusion of pharmacy in NHS guidance and protocols for frontline primary care staff for better communication; temporary registration of pharmacy professionals; and sticking to 28-day supply and electronic repeat dispensing for suitable patients.

More For You

Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less